Access to Medicine Foundation | 2020 Antimicrobial Resistance (AMR) Benchmark

The World Bank has warned that the annual costs associated with drug-resistant infections could be as large as those of the global financial crisis that started in 2008. The Access to Medicine Foundation's AMR Benchmark is the first and only independent measure of how pharmaceutical companies involved in developing and supplying antibacterial and antifungal medicines and vaccines are taking action to limit AMR. The 2020 AMR Benchmark has evaluated for the second time how the most important players in the antibiotic market are addressing the rise of resistance and the global need for appropriate access to antibiotics.Overall, the Benchmark includes metrics for 8 large research-based pharmaceutical companies, 9 generic medicine manufacturers, and 13 small and medium-sized enterprises.

Share this